Higher antibody titers and a growing demand for smaller-volume, flexible processes are creating the need for more cost-effective downstream processing. Changes in the biopharmaceuticals market are ...
Biomanufacturing is different from other processing industries. It is less able to sustain continuous end-to-end flows because it must contend with unique technical, practical, regulatory, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results